Opus Genetics (IRD) Change in Receivables (2022 - 2026)
Opus Genetics (IRD) reported Change in Receivables of -$264000.0 for Q1 2026, up 45.34% year-over-year from -$181641.0 in Q1 2025, and up 71.34% on a QoQ basis from -$921000.0 in Q4 2025.
Opus Genetics (IRD) has 5 years of Change in Receivables data on file, last reported at -$264000.0 in Q1 2026.
- Quarterly Change in Receivables rose 45.34% year-over-year to -$264000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.3 million (down 216.7% YoY) and the FY2025 annual result came in at -$1.6 million, down 159.46% from the prior year.
- Change in Receivables grew to -$264000.0 in Q1 2026 per IRD's latest filing, from -$921000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $10.0 million in Q3 2023 and bottomed at -$9.2 million in Q4 2023.
- The 5-year median for Change in Receivables is $27500.0 (2025), against an average of $123642.9.
- The widest annual swing landed in 2023, when Change in Receivables tumbled 809.24%; it then jumped 156.36% in 2025.
- Tracing IRD's Change in Receivables over 5 years: stood at $1.3 million in 2022, then plunged by 809.24% to -$9.2 million in 2023, then jumped by 118.53% to $1.7 million in 2024, then slumped by 153.99% to -$921000.0 in 2025, then soared by 71.34% to -$264000.0 in 2026.
- Per Business Quant, the three latest IRD Change in Receivables figures stand at -$264000.0 (Q1 2026), -$921000.0 (Q4 2025), and -$483000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 208,524.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -39.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -1.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 110.42 Mn |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - | -264,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -264,000.00 |
| Mar 31, 2026 | -264,000.00 |
| Dec 31, 2025 | -921,000.00 |
| Dec 31, 2025 | -921,000.00 |
| Sep 30, 2025 | -483,000.00 |
| Sep 30, 2025 | -483,000.00 |
| Jun 30, 2025 | 319,000.00 |
| Jun 30, 2025 | 319,000.00 |
| Mar 31, 2025 | -483,000.00 |
| Mar 31, 2025 | -483,000.00 |
| Dec 31, 2024 | 1.71 Mn |
| Dec 31, 2024 | 1.71 Mn |
| Sep 30, 2024 | 499,000.00 |
| Sep 30, 2024 | 499,000.00 |
| Jun 30, 2024 | -566,000.00 |
| Jun 30, 2024 | -566,000.00 |
| Mar 31, 2024 | 998,000.00 |
| Mar 31, 2024 | 998,000.00 |
| Dec 31, 2023 | -9.21 Mn |
| Dec 31, 2023 | -9.21 Mn |
| Sep 30, 2023 | 10.00 Mn |
| Sep 30, 2023 | 10.00 Mn |
| Jun 30, 2023 | -2.70 Mn |
| Jun 30, 2023 | -2.70 Mn |
| Mar 31, 2023 | 1.54 Mn |
| Mar 31, 2023 | 1.54 Mn |
| Dec 31, 2022 | 1.30 Mn |
| Dec 31, 2022 | 1.30 Mn |